Navigating adalimumab biosimilars: an expert opinion
The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars – (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma – for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyri...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-10-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |